Benedicte Dubois

List of Publications by Year
in descending order

61	9,091	236612	155451
papers	citations	25 h-index	55 g-index

62	62	62	14385
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
2	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
3	Multiple Sclerosis Severity Score. Neurology, 2005, 64, 1144-1151.	1.5	836
4	Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9). Critical Reviews in Biochemistry and Molecular Biology, 2002, 37, 375-536.	2.3	805
5	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	6.0	710
6	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
7	Interleukin 7 receptor Î± chain (IL7R) shows allelic and functional association with multiple sclerosis. Nature Genetics, 2007, 39, 1083-1091.	9.4	578
8	Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113.	9.4	312
9	The role of the CD58 locus in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5264-5269.	3.3	185
10	Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood, 2011, 118, 1693-1698.	0.6	140
11	CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells. Nature Communications, 2015, 6, 8644.	5.8	117
12	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	13.5	115
13	Gelatinase B deficiency protects against endotoxin shock. European Journal of Immunology, 2002, 32, 2163.	1.6	81
14	In VivoNeutrophil Recruitment by Granulocyte Chemotactic Protein-2 Is Assisted by Gelatinase B/MMP-9 in the Mouse. Journal of Interferon and Cytokine Research, 2000, 20, 667-674.	0.5	69
15	Mitochondrial mutations of Leber's hereditary optic neuropathy: a risk factor for multiple sclerosis. Journal of Neurology, 2000, 247, 535-543.	1.8	61
16	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643.	3.7	54
17	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain, 2018, 141, 786-796.	3.7	39
18	Replication of KIF21B as a susceptibility locus for multiple sclerosis. Journal of Medical Genetics, 2010, 47, 775-776.	1.5	38

#	Article	IF	Citations
19	Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Annals of Neurology, 2013, 73, 86-94.	2.8	38
20	LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 129-135.	1.1	37
21	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	2.1	36
22	Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators. Cell Reports, 2018, 25, 798-810.e6.	2.9	36
23	Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e240.	3.1	35
24	Corticosteroids in the management of acute multiple sclerosis exacerbations. Acta Neurologica Belgica, 2017, 117, 623-633.	0.5	31
25	Somatic Variants: New Kids on the Block in Human Immunogenetics. Trends in Genetics, 2019, 35, 935-947.	2.9	29
26	Burden of risk variants correlates with phenotype of multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1670-1680.	1.4	27
27	Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. Journal of Neuroimmunology, 1999, 95, 195-201.	1.1	24
28	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 1916-1922.	1.4	23
29	Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	23
30	Regulation of gelatinase B (MMP-9) in leukocytes by plant lectins. FEBS Letters, 1998, 427, 275-278.	1.3	22
31	CHIT1 at Diagnosis Reflects Longâ€Term Multiple Sclerosis Disease Activity. Annals of Neurology, 2020, 87, 633-645.	2.8	22
32	Regulation of gelatinases in microglia and astrocyte cell cultures by plant lectins. , 1999, 27, 53-61.		20
33	Progress in Multiple Sclerosis Genetics. Current Genomics, 2012, 13, 646-663.	0.7	20
34	Gelatinase B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis. Journal of the Neurological Sciences, 2002, 200, 43-48.	0.3	19
35	Gelatinase B in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neurologica Belgica, 1999, 99, 53-6.	0.5	19
36	Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 1998, 4, 74-78.	1.4	18

#	Article	IF	Citations
37	TNFRSF1A coding variants in multiple sclerosis. Journal of Neuroimmunology, 2011, 235, 110-112.	1.1	16
38	A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease. Human Molecular Genetics, 2019, 28, 1369-1380.	1.4	16
39	HLA-E restricted CD8+ T cell subsets are phenotypically altered in multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 790-801.	1.4	14
40	Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies. Journal of Neurology, 2022, 269, 4565-4574.	1.8	14
41	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3: Genes, Genomes, Genetics, 2016, 6, 2073-2079.	0.8	13
42	Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation. Multiple Sclerosis Journal, 2018, 24, 1773-1775.	1.4	13
43	New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium. Multiple Sclerosis Journal, 2017, 23, 29-40.	1.4	12
44	Genetic Variation in <scp>WNT9B</scp> Increases Relapse Hazard in Multiple Sclerosis. Annals of Neurology, 2021, 89, 884-894.	2.8	12
45	Body Mass Index, Interleukin-6 Signaling and Multiple Sclerosis: A Mendelian Randomization Study. Frontiers in Immunology, 2022, 13, 834644.	2.2	12
46	Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. Acta Neurologica Belgica, 2018, 118, 7-11.	0.5	10
47	Characteristic callosal involvement in Susacâ€™s syndrome. Acta Neurologica Belgica, 2015, 115, 395-396.	0.5	7
48	Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease. Multiple Sclerosis Journal, 2013, 19, 1132-1136.	1.4	6
49	A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurologica Belgica, 2018, 118, 161-168.	0.5	6
50	Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 676619.	2.2	6
51	Quantitative MRI phenotypes capture biological heterogeneity in multiple sclerosis patients. Scientific Reports, 2021, 11, 1573.	1.6	5
52	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	0.4	3
53	Role of Genetic Factors in Pathophysiology of Multiple Sclerosis. , 2016, , 153-180.		2
54	Leveraging human genetics to inform intervention strategies for multiple sclerosis. Neurology, 2019, 92, 735-736.	1.5	2

#	Article	IF	Citations
55	Antiviral treatment with fluoxetine for rituximabâ€associated chronic echovirus 13 meningoencephalitis and myofasciitis. European Journal of Neurology, 0, , .	1.7	2
56	Corrigendum to â€œPixantrone (BBR2778): A new immunosuppressant in multiple sclerosis with a low cardiotoxicityâ€•[J Neurol Sci 223 (2004) 81â€“86]. Journal of the Neurological Sciences, 2005, 235, 79.	0.3	1
57	Corrigendum to â€œLinkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeansâ€•[J. Neuroimmunol. 179 (2006) 108â€“116]. Journal of Neuroimmunology, 2007, 189, 175-176.	1.1	1
58	Horizontal saccadic palsy as a prominent symptom of anti-NMDAR encephalitis. Neurology: Clinical Practice, 2019, 11, 10.1212/CPJ.0000000000000750.	0.8	0
59	Community-acquired bacterial meningitis in adults: emergency department management protocol. Acta Neurologica Belgica, 2020, 120, 1033-1043.	0.5	0
60	The immunological basis of current and novel therapies of multiple sclerosis. Archivum Immunologiae Et Therapiae Experimentalis, 1999, 47, 7-16.	1.0	0
61	Neurocysticercosis: An Uncommon Cause of Acute Supratentorial Hydrocephalus. Journal of the Belgian Society of Radiology, 2022, 106, 31.	0.1	0